INTERSTIM WITHOUT LIMITS™

YOUR BEST CHOICE FOR SACRAL NEUROMODULATION

InterStim™ II System

InterStim™ Micro System

Indications for Use:

Sacral Neuromodulation delivered by the InterStim™ system for Urinary Control is indicated for the treatment of urinary retention and the symptoms of overactive bladder, including urinary urge incontinence and significant symptoms of urgency-frequency alone or in combination, in patients who have failed or could not tolerate more conservative treatments.

The following Warning applies only to Sacral Neuromodulation for Urinary Control:

Warning: This therapy is not intended for patients with mechanical obstruction such as benign prostatic hypertrophy, cancer, or urethral stricture.

Sacral Neuromodulation delivered by the InterStim™ system for Bowel Control is indicated for the treatment of chronic fecal incontinence in patients who have failed or are not candidates for more conservative treatments.

Contraindications for Urinary Control and for Bowel Control: Diathermy. Patients who have not demonstrated an appropriate response to test stimulation or are unable to operate the neurostimulator.

Warnings/Precautions/Adverse Events:

For Urinary Control: Safety and effectiveness have not been established for bilateral stimulation; pregnancy, unborn fetus, and delivery; pediatric use under the age of 16; or for patients with neurological disease origins.

For Bowel Control: Safety and effectiveness have not been established for bilateral stimulation; pregnancy, unborn fetus, and delivery; pediatric use under the age of 18; or for patients with progressive, systemic neurological diseases.

For Urinary Control and for Bowel Control: The system may be affected by or adversely affect cardiac devices, electrocautery, defibrillators, ultrasonic equipment, radiation therapy, MRI, theft detectors/ screening devices. Adverse events include pain at the implant sites, new pain, lead migration, infection, technical or device problems, adverse change in bowel or voiding function, and undesirable stimulation or sensations, including jolting or shock sensations. Patients should be assessed preoperatively for the risk of increased bleeding. For full prescribing information, please call Medtronic at 1-800-328-0810 and/or consult Medtronic's website at www.medtronic.com. Product technical manual must be reviewed prior to use for detailed disclosure.

USA Rx Only. Rev 0517

Medtronic

710 Medtronic Parkway
Minneapolis, MN 55432-5604
USA
Tel: (763) 514-4000

medtronic.com

INTERSTIM WITHOUT LIMITS™

YOUR BEST CHOICE FOR SACRAL NEUROMODULATION



Medtronic

BEST CHOICE
YOUR CHOICE

Choose the Best InterStim™ System for Each Patient

Both systems are full-body* MRI eligible and deliver the same therapy with long-term relief.

INTERSTIM™ II RECHARGE-FREE SYSTEM

- Simple
- Convenient
- Lower maintenance

INTERSTIM™ MICRO RECHARGEABLE SYSTEM

- Smaller in size
- Longer battery life
- Requires regular recharging sessions

PATIENT MANAGEMENT WITHOUT LIMITS

With the InterStim™ smart programmer, you benefit from a single programming platform across both recharge-free and rechargeable devices.

- Allows you to choose up to 11 programs
- Allows patients to manage their experience easily at home or on-the-go

*Under certain conditions; see approved labeling for details. Patients with InterStim™ SureScan™ MRI leads only.

RELIEF
WITHOUT LIMITS

InterStim™ II – Recharge-free System

The ONLY recharge-free SNM device available. Proprietary SureScan™ MRI technology expands eligibility and allows patients with the InterStim™ II system to get full-body* 1.5T and 3T MRI scans.

- The recharge-free InterStim™ II system may be best for most patients because it's simple, convenient, and low maintenance.
- Full-body* MRI 1.5T and 3T
- Gives patients the freedom of relief without a recharging routine
- Delivers sustained improvements in quality of life[1,2]
- More than 325,000 patients treated worldwide
- Only SNM device with five-year clinical data demonstrating sustained efficacy[1,2]

82%
of OAB patients achieved clinical success at 5 years†

45%
of urinary incontinence patients were completely continent at 5 years†

The most common adverse events experienced during clinical studies include pain at implant sites, new pain, lead migration, infection, technical or device problems, adverse change in bowel or voiding function, and undesirable stimulation or sensations. Any of these may require additional surgery or cause return of symptoms.

*Under certain conditions; see approved labeling for details. Patients with InterStim™ SureScan™ MRI Leads only.

†Numbers reflect completers analysis defined as patients with diary data at baseline and 5 years.

1. Siegel, Steven: Five Year Follow-up Results of a Prospective, Multicenter Study in Overactive Bladder Subjects Treated with Sacral Neuromodulation. The Journal of Urology. 2018;Volume 199(1), 229–236.

2. Hull T, Giese C, Wexner SD, Mellgren A, Devroede G, et al. Long-term durability of sacral nerve stimulation therapy for chronic fecal incontinence. Dis Colon Rectum. 2013;56:234–245.

RECHARGE
WITHOUT LIMITS

InterStim™ Micro – Rechargeable System

Proprietary SureScan™ MRI technology expands eligibility and allows patients with the InterStim™ Micro system to get full-body* 1.5T and 3T MRI scans.

Not all batteries are created equal

WITH OVERDRIVE™ BATTERY TECHNOLOGY, INTERSTIM™ MICRO IS:

SMALLER
- The InterStim™ Micro neurostimulator is the smallest sacral neuromodulation device on the market

BETTER
- No battery fade at 15 years**

FASTER
- Recharge in 20 minutes, once a week.†
- Recharge from zero to 100% in less than an hour§

STRONGER
- Unaffected by patient recharging preferences

*Under certain conditions; see approved labeling for details.
**Under standard patient therapy settings.
†Under standard patient therapy settings and appropriate recharger placement.
§Based on appropriate recharger placement.